Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 588

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 588
---
 course matters will not have a material adverse effect on Kineta’s business. Regardless of the outcome, litigation can have an adverse impact
on Kineta because of defense and settlement costs, diversion of management resources and other factors.

Corporate Information

Kineta was incorporated in Delaware on December 13, 2006 under the name Proteoguard, Inc. and subsequently changed Kineta’s name to
Proteostasis Therapeutics, Inc. on September 17, 2007. On December 22, 2020, Kineta effected a reverse merger, pursuant to which a wholly-owned subsidiary of ours merged with and into Yumanity with Yumanity surviving as a wholly-owned
subsidiary of ours. On December 22, 2020, Kineta changed Kineta’s name from “Proteostasis Therapeutics, Inc.” to “Yumanity Therapeutics, Inc.” On December 16, 2022, Kineta effected a reverse merger, pursuant
to which a wholly-owned subsidiary of ours merged with and into Private Kineta with Private Kineta surviving as a wholly-owned subsidiary of ours. Private Kineta subsequently merged with and into Kineta Operating, LLC, with Kineta Operating,
LLC being the surviving corporation. On December 16, 2022, Kineta changed Kineta’s name from “Yumanity Therapeutics, Inc.” to “Kineta, Inc.” Kineta’s principal executive offices are located at 7683 SE 27th Street,
Suite 481, Mercer Island, Washington 98040. Kineta’s telephone number is (206) 378-0400. Kineta’s website address is https://kinetabio.com.

Available Information

Kineta’s
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and
information statements and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act, are available through the “Investors” portion of Kineta’s website at https://kinetabio.com free
of charge as soon as reasonably practicable after Kineta electronically files such material with, or furnish it to, the SEC. Information on Kineta’s website is not part of, or incorporated by reference into, this joint proxy
statement/prospectus or any other report Kineta files with, or furnish to, the SEC. In addition, Kineta’s filings with the SEC may